| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5806947 | Current Opinion in Virology | 2012 | 5 Pages |
The approval of direct-acting antiviral agents (DAAs) against the hepatitis C virus (HCV) NS3 protease revolutionized antiviral therapy in chronic hepatitis C. They mark the beginning of an era with drugs designed to inhibit specific viral proteins involved in the virus life cycle rather than the nonspecific antiviral activity of interferon. Upcoming generations of antivirals are expected that lead to viral eradication in most patients who undergo treatment with hope held for years that HCV can be cured without interferon. Antiviral drug resistance plays a key role in DAA-treatment failure. Knowledge on molecular escape mechanisms of resistant variants, their time to wild-type reversal and potential persistence is of upmost importance to design treatment strategies for patients with previous DAA-treatment failure.
⺠Key principles to resistance development. ⺠Role of Peg-IFN/RBV. ⺠Fate of resistant viral variants. ⺠Re-treatment upon PI-failure.
